What is RNXT's current stock price?

RNXT (RenovoRx, Inc.) is currently trading at $0.88 with a market cap of $32.8M.

What sector is RenovoRx, Inc. in?

RenovoRx, Inc. (RNXT) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

RNXT RenovoRx, Inc.

Healthcare

$0.88-0.01%ClosedMarket Cap: $32.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.98

P/S

22.04

EV/EBITDA

-1.60

DCF Value

$0.92

FCF Yield

-34.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

78.7%

Operating Margin

-864.3%

Net Margin

-824.0%

ROE

-138.6%

ROA

-87.9%

ROIC

-106.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$563.0K	$-3.5M	$—
Q4 null	$238.0K	$-2.9M	$—
FY null	$1.1M	$-11.2M	$—
Q3 null	$266.0K	$-2.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-04-09

HC Wainwright & Co.Buy

2026-04-08

Ascendiant CapitalBuy

2026-02-17

Ascendiant CapitalBuy

2025-11-21

Ascendiant CapitalBuy

2025-08-25

Trading Activity

Insider Trades

View All

VOLL MARKofficer: Chief Financial Officer

BuyThu May 21

VOLL MARKofficer: Chief Financial Officer

SellTue Apr 07

Gentry Leesaofficer: Chief Clinical Officer

SellTue Apr 07

Bagai Shaundirector, officer: Chief Executive Officer

SellTue Apr 07

Agah Ramtindirector, officer: Chief Medical Officer

SellTue Apr 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.00

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Peers